EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Molecular Profiling and Tumor Microenvironment in Sinonasal Mucosal Melanoma as Biomarkers for Enhanced Prognostic Stratification

Manuel Molina-Garcia iD, Maria Jesus Rojas-Lechuga iD, Cristobal Langdon, Judit Mateu iD, Jaume Bague, Teresa Torres, Vinicius G de Souza, Manuel Bernal-Sprekelsen, Isam Alobid, Rui Milton Patricio da Silva-Júnior, Susana Puig

International Forum of Allergy & Rhinology · 2025

DOI: 10.1002/alr.23606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Manuel Molina-Garcia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Hauptthemen laut MEDLINE: Melanoma, Tumor Microenvironment, Biomarkers, Tumor, Paranasal Sinus Neoplasms. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, European Union, Ministerio de Ciencia, Innovación y Universidades.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sinonasal mucosal melanoma (SNMM) is a rare and aggressive melanoma subtype with a notably poor prognosis. Despite molecular characterization advances, SNMM remains clinically challenging, highlighting the need for detailed molecular profiling. This study aimed to identify the molecular features of SNMM, elucidate its prognostic implications, and provide insights for improved therapies.

Methods

Sixteen SNMM tumors were retrospectively analyzed at the Hospital Clinic of Barcelona. Next‐generation sequencing targeted 1392 immuno‐oncology‐related probes. Log‐rank test, hierarchical clustering analysis (HCA), Cox regression, differentially expressed genes, gene set enrichment analysis, and the xCell algorithm were performed. Statistical analyses comprised descriptive statistics, clinical variable associations, and survival analyses.

Results

Among 16 tumors, 107 genes significantly correlated with melanoma‐specific survival (MSS) ( p < 0.05). HCA based on these genes revealed two clusters: Cluster B showed poorer prognosis (median MSS: 11.73 months; Q1: 8.74, Q3: 30.78) compared to Cluster A (median MSS: 81.74 months; Q1: 32.82, Q3: 92.44; p = 0.0051). Cox regression identified staging and molecular clustering as independent MSS predictors, with Cluster B exhibiting a hazard ratio of 13.23 (95% confidence intervals [CI]: 1.503–116.48, p = 0.02). Cluster B tumors displayed upregulated cell cycle genes and reduced infiltration of CD4+, CD8+, Th1, and B cells.

Conclusions

Molecular profiling in SNMM provides prognostic information beyond standard clinical parameters. Cell cycle and immune‐related gene expression patterns, together with decreased infiltration of CD4+, CD8+, Th1, and B cells, correlate with poorer MSS. Integrating molecular profiling with clinical staging could improve risk assessment and help identify high‐risk patients for tailored therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaTumor MicroenvironmentBiomarkers, TumorParanasal Sinus NeoplasmsNasal MucosaHumansFemaleMalePrognosisMiddle AgedAgedRetrospective StudiesAdultGene Expression ProfilingLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

biomarkersgene expression profilingimmune cellslymphocytesnasal cavitytranscriptometumor microenvironmenttumor‐infiltrating

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Department of Medicine, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, Spain.
  • Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Otorhinolaryngology Department, Hospital Clinic of Barcelona, CIBERES, Barcelona, Spain.
  • Otorhinolaryngology Department, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Centre of Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.

ORCID-Profile: Manuel Molina-Garcia, Maria Jesus Rojas-Lechuga, Judit Mateu

Förderung

  • Instituto de Salud Carlos III
  • European Union
  • Ministerio de Ciencia, Innovación y Universidades
  • "la Caixa" Foundation
  • European Commission

Zitieren

APA

Molina-Garcia, M., Rojas-Lechuga, M. J., Langdon, C., Mateu, J., Bague, J., Torres, T., de Souza, V. G., Bernal-Sprekelsen, M., Alobid, I., da Silva-Júnior, R. M. P., & Puig, S. (2025). Molecular Profiling and Tumor Microenvironment in Sinonasal Mucosal Melanoma as Biomarkers for Enhanced Prognostic Stratification. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23606

Vancouver

Molina-Garcia M, Rojas-Lechuga MJ, Langdon C, Mateu J, Bague J, Torres T, et al. Molecular Profiling and Tumor Microenvironment in Sinonasal Mucosal Melanoma as Biomarkers for Enhanced Prognostic Stratification. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23606

BibTeX
@article{MolinaGarcia2025,
  author = {Molina-Garcia, Manuel and Rojas-Lechuga, Maria Jesus and Langdon, Cristobal and Mateu, Judit and Bague, Jaume and Torres, Teresa and de Souza, Vinicius G and Bernal-Sprekelsen, Manuel and Alobid, Isam and da Silva-Júnior, Rui Milton Patricio and Puig, Susana},
  title = {Molecular Profiling and Tumor Microenvironment in Sinonasal Mucosal Melanoma as Biomarkers for Enhanced Prognostic Stratification},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  doi = {10.1002/alr.23606}
}
Kostenlos starten →